Key facts
- This page summarizes John Glenn's Form 4 filing for IRADIMED CORP (IRMD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jun 2023, 16:30.
John Glenn - 20 Jun 2023 Form 4 Insider Report for IRADIMED CORP (IRMD)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- IRMD
- Reported as of
- 20 Jun 2023
- Net transaction value
- -$67,607
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2023, 16:30:13 UTC
- Prior SEC filing
- 16 Dec 2022
- Next SEC filing
- 11 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Glenn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Glenn filed Form 4 for IRADIMED CORP (IRMD) on 22 Jun 2023.
Change
- Previous filing in this sequence was filed on 16 Dec 2022.
- Current net transaction value: -$67,607.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRMD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,795
- Change %
- +232%
- Price
- Shares after
- 8,295
- Date
- 20 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
IRMD
transaction
Common Stock
Tax liability
- Transaction value
- $67,607
- Shares
- -1,412
- Change %
- -17%
- Price
- $47.88
- Shares after
- 6,883
- Date
- 20 Jun 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,795
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 17,388
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,795
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
On June 20, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.